Catalent (NYSE:CTLT) was downgraded by Zacks Investment Research from a "buy" rating to a "hold" rating in a research report issued on Wednesday, Zacks.com reports.
According to Zacks, "Catalent, Inc. provides advanced delivery technologies and development solutions for drugs, biologics and consumer health products. It operates through Oral Technologies, Medication Delivery Solutions, and Development & Clinical Services. The Oral Technologies segment address the full diversity of the pharmaceutical industry including small molecules, large molecule biologics and consumer health products. The Medication Delivery Solutions segment offers formulation, development, and manufacturing services for delivery of drugs and biologics administered through injection, inhalation, and ophthalmic routes. The Development and Clinical Services segment provides manufacturing, packaging, storage, and inventory management services for drugs and biologics in clinical trials. Catalent, Inc. is headquartered in Somerset, New Jersey. "
Several other analysts also recently weighed in on the stock. Jefferies Financial Group lifted their target price on shares of Catalent from $107.00 to $115.00 and gave the company a "buy" rating in a report on Wednesday, November 4th. Royal Bank of Canada lifted their target price on shares of Catalent from $98.00 to $105.00 and gave the company an "outperform" rating in a report on Wednesday, November 4th. Morgan Stanley lifted their target price on shares of Catalent from $98.00 to $115.00 and gave the company an "overweight" rating in a report on Wednesday, November 4th. JPMorgan Chase & Co. lifted their target price on shares of Catalent from $110.00 to $130.00 and gave the company an "overweight" rating in a report on Friday, January 8th. Finally, BidaskClub upgraded shares of Catalent from a "hold" rating to a "buy" rating in a report on Tuesday, December 22nd. Two research analysts have rated the stock with a hold rating and nine have assigned a buy rating to the stock. The company currently has an average rating of "Buy" and a consensus target price of $110.30.
CTLT traded down $0.94 during midday trading on Wednesday, hitting $114.75. 787,642 shares of the company were exchanged, compared to its average volume of 1,152,057. The company's 50 day simple moving average is $101.40 and its 200 day simple moving average is $91.31. The firm has a market capitalization of $18.90 billion, a price-to-earnings ratio of 73.09, a price-to-earnings-growth ratio of 2.61 and a beta of 1.50. The company has a current ratio of 2.56, a quick ratio of 2.14 and a debt-to-equity ratio of 0.97. Catalent has a 1-year low of $31.04 and a 1-year high of $120.48.
Catalent (NYSE:CTLT) last issued its quarterly earnings results on Tuesday, November 3rd. The company reported $0.43 earnings per share for the quarter, beating the Zacks' consensus estimate of $0.37 by $0.06. The firm had revenue of $845.70 million for the quarter, compared to analyst estimates of $812.87 million. Catalent had a net margin of 9.25% and a return on equity of 14.20%. Catalent's quarterly revenue was up 27.2% compared to the same quarter last year. During the same period last year, the company posted $0.26 EPS. On average, equities analysts anticipate that Catalent will post 2.35 EPS for the current year.
In other news, insider Aristippos Gennadios sold 13,662 shares of Catalent stock in a transaction on Monday, December 21st. The shares were sold at an average price of $102.84, for a total transaction of $1,405,000.08. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, SVP Steven L. Fasman sold 2,425 shares of Catalent stock in a transaction on Wednesday, November 11th. The stock was sold at an average price of $100.99, for a total transaction of $244,900.75. The disclosure for this sale can be found here. Insiders sold a total of 19,163 shares of company stock valued at $1,990,667 in the last three months. 1.00% of the stock is currently owned by corporate insiders.
Institutional investors have recently added to or reduced their stakes in the company. HM Payson & Co. purchased a new stake in shares of Catalent during the 3rd quarter worth $25,000. Paces Ferry Wealth Advisors LLC purchased a new stake in Catalent in the third quarter valued at $31,000. Ellevest Inc. purchased a new stake in Catalent in the third quarter valued at $45,000. First Horizon Advisors Inc. lifted its position in Catalent by 120.6% in the third quarter. First Horizon Advisors Inc. now owns 556 shares of the company's stock valued at $47,000 after acquiring an additional 304 shares during the last quarter. Finally, C M Bidwell & Associates Ltd. purchased a new stake in Catalent in the third quarter valued at $108,000. 97.84% of the stock is owned by institutional investors and hedge funds.
Catalent, Inc, together with its subsidiaries, provides delivery technologies and development solutions for drugs, biologics, and consumer and animal health products worldwide. It operates through four segments: Softgel and Oral Technologies, Biologics, Oral and Specialty Delivery, and Clinical Supply Services.
Recommended Story: What is an Initial Public Offering (IPO)?
Get a free copy of the Zacks research report on Catalent (CTLT)
For more information about research offerings from Zacks Investment Research, visit Zacks.com
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to [email protected]
7 Stocks to Support Your New Year’s Resolutions
After a year like 2020, many Americans figure that just getting to 2021 was enough. But for many people, the start of a new year still means making resolutions. And while many Americans are still waking up to Groundhog’s Day, there is hope that things will look dramatically different in September than they do right now.
Some of the most popular resolutions include losing weight, exercising more, or taking steps to get our life and/or business more organized. And many pure-play companies lean into these trends and are doing well.
As an alternative to this, you can also invest in companies that are not pure plays but can still benefit from consumers looking to start fresh. Owning these stocks helps you manage your risk. If the trend holds, you can ride the wave. On the other hand, if the wave turns into a ripple, the stocks have other catalysts to get them through.
In this special presentation, we’ll take a look at both of these categories. We’ve got several pure-play companies that let investors buy stocks in companies benefiting from these trends. We’ll also give you a few stocks that fall in the latter category.
These are stocks that you might buy at any time and for many reasons. However, they present excellent buys as the new year begins.
View the "7 Stocks to Support Your New Year’s Resolutions".